Program | Friday

 
09:00 — Welcome
B. Meder, Director ICH.
Welcome
N. Frey, Director Department Cardiology
09:15 — RNA splicing: pathogenesis and novel treatments
Chairs: E. Ashley, Stanford; M. van den Hoogenhof, Heidelberg
Titin as a therapeutic target
M. Gotthardt, Berlin
MYBPC3 missplicing
M. Carmo-Fonseca, Lisbon
High risk genes causing arrhythmogenic DCM
V. Parikh, Stanford
Talk young investigator Leducq
10:15 — Arrhythmia & atrial cardiomyopathy: novel concepts
Chairs: N. Frey, Heidelberg; P. Lugenbiel, Heidelberg
Engineered heart tissue to model atrial and ventricular pathologies
T. Eschenhagen, Hamburg
Which VT is ablatable, which needs an ICD?
T. Lewalter, Munich
Is the ICD overused?
Spotlights from our friends in Australia and Japan
11:15 — The Leducq keynote
Chair: Hugo A. Katus, Heidelberg
AI & cardiomyopathy: the final frontier?
Euan Ashley, Stanford
12:00 — LUNCH BREAK – poster session & meet your idol in the speaker corner
13:00 — Myocardial inflammation – insights and novel treatments
Chairs: J. Backs, Heidelberg; H.-P. Schultheiß, Berlin
Targeting myocardial inflammation
S. Heymans, Maastricht
Treatment of mitochondrial cardiomyopathy
C. Maack, Würzburg
Talk young investigator
What is the treatment reality for myocarditis?
Spotlights from our friends in Africa
14:00 — Cardiac myosin inhibitors in hypertrophic cardiomyopathy
Chairs: S. Klaassen, Berlin; F. Sedaghat-Hamedani, Heidelberg
Myosin inhibition: possibilities beyond obstruction
I. Olivotto, Florence
Modulating sarcomere dynamics in hypertrophic cardiomyopathy
J. van der Velden, Amsterdam
Myosin inhibition and arrhythmia burden – is there a link?
P. Elliott, London
MYBPC3 related disease mechanisms and treatment
L. Carrier, Hamburg
15:00 — COFFEE BREAK
15:30 — From mendelian disease to population genetics
Chairs: J. Haas, Heidelberg; C. Schaaf, Heidelberg
Novel therapeutic targets by multitrait analyses
C. Bezzina, Amsterdam
Atrial fibrillation – do we understand it by genetics
S. Kääb, Munich
The case of intermediate frequency intermediate-effect variants
R. Walsh, Amsterdam
Polygenic risk scores: the evidence so far
J. Ware, London
16:30 — Rare cardiomyopathies and novel RNA and DNA therapies
Chairs: N. Frey, Heidelberg; E. Kayvanpour, Heidelberg
Genome editing – from rare to common
S. Lebek, Regensburg
Deciphering new disease mechanisms in genetic cardiomyopathies
E. van Rooij, Utrecht
RNA therapies in cardiomyopathies
Y. Pinto, Amsterdam
Are Europeans overcautious with gene therapies?
Spotlights from our friends in the US
17:30 — New technologies for cardiomyopathy care
Chairs: G. Dobreva, Mannheim; F. Leuschner, Heidelberg
Single-cell transcriptomics in the study of cardiac disease
M. Noseda, London
Tackling spatial information and cellular heterogeneity
N. Hübner, Berlin
Artificial intelligence: how to advance and implement
F. Asselbergs, Amsterdam
Multimodality imaging in the cardiomyopathies
E. Biagini, Bologna
From 18:30 — GET TOGETHER